Loading...
XSHE002750
Market cap141mUSD
Dec 23, Last price  
2.57CNY
1D
-4.81%
1Q
23.56%
Jan 2017
-84.31%
IPO
-48.85%
Name

Kunming Longjin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHE:002750 chart
P/E
—
P/S
11.88
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-0.02%
Rev. gr., 5y
-23.75%
Revenues
87m
-29.56%
148,557,614182,133,218178,852,941187,402,083181,428,197223,631,229304,447,655335,984,894275,292,322254,026,717702,518,674122,965,51286,622,523
Net income
-71m
69,660,106100,200,38475,055,87963,572,96761,801,11191,034,39735,159,52813,870,10307,754,24900-70,941,451
CFO
-39m
75,898,51191,163,317106,458,24270,162,98670,185,159104,238,68858,057,42931,698,7974,043,279000-39,260,749
Dividend
May 23, 20180.03 CNY/sh
Earnings
May 21, 2025

Profile

Kunmig Longjin Pharmaceutical Co., Ltd. develops, produces, and sells natural botanicals and chemical freeze-dried powder injections in China. The company offers Chinese, biochemical, chemical, cardio-cerebral vascular, and digestive system medicines; immune system and first aid medications; and vitamins, minerals, and enteral and parenteral nutrition products. It also engages in the industrial hemp plantation business. The company was founded in 1996 and is headquartered in Kunming, China.
URL
http://www.longjin.com.cn/
IPO date
Mar 24, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
86,623
-29.56%
122,966
-82.50%
702,519
176.55%
Cost of revenue
130,822
140,085
677,256
Unusual Expense (Income)
NOPBT
(44,200)
(17,120)
25,263
NOPBT Margin
3.60%
Operating Taxes
2,020
4,799
1,896
Tax Rate
7.51%
NOPAT
(46,220)
(21,919)
23,367
Net income
(70,941)
 
Dividends
Dividend yield
Proceeds from repurchase of equity
(670)
BB yield
0.02%
Debt
Debt current
171
164
Long-term debt
1,609
1,967
2,310
Deferred revenue
39,492
41,501
34,434
Other long-term liabilities
12,298
34,434
Net debt
(332,960)
(402,208)
(427,018)
Cash flow
Cash from operating activities
(39,261)
CAPEX
(15,665)
Cash from investing activities
56,040
115,999
Cash from financing activities
2,885
(12,523)
22,435
FCF
(24,120)
(1,144)
47,535
Balance
Cash
334,149
404,347
429,491
Long term investments
420
Excess cash
330,238
398,199
394,366
Stockholders' equity
490,134
604,653
678,181
Invested Capital
251,185
251,173
345,988
ROIC
6.81%
ROCE
3.58%
EV
Common stock shares outstanding
400,500
400,500
400,500
Price
10.00
-10.15%
11.13
-31.00%
16.13
92.48%
Market cap
4,005,000
-10.15%
4,457,565
-31.00%
6,460,065
92.48%
EV
3,701,279
4,077,092
6,072,194
EBITDA
(13,611)
12,667
56,100
EV/EBITDA
321.88
108.24
Interest
13,182
469
Interest/NOPBT
1.86%